326 related articles for article (PubMed ID: 19293270)
1. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
Neto LV; Machado Ede O; Luque RM; Taboada GF; Marcondes JB; Chimelli LM; Quintella LP; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
J Clin Endocrinol Metab; 2009 Jun; 94(6):1931-7. PubMed ID: 19293270
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
[TBL] [Abstract][Full Text] [Related]
3. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
Vieria Neto L; Wildemberg LE; Colli LM; Kasuki L; Marques NV; Moraes AB; Gasparetto EL; Takiya CM; Castro M; Gadelha MR
PLoS One; 2013; 8(10):e77406. PubMed ID: 24098585
[TBL] [Abstract][Full Text] [Related]
4. Impact of gsp oncogene on the mRNA content for somatostatin and dopamine receptors in human somatotropinomas.
Taboada GF; Neto LV; Luque RM; Córdoba-Chacón J; de Oliveira Machado E; de Carvalho DP; Kineman RD; Gadelha MR
Neuroendocrinology; 2011; 93(1):40-7. PubMed ID: 21079388
[TBL] [Abstract][Full Text] [Related]
5. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
[TBL] [Abstract][Full Text] [Related]
6. Genetic abnormalities of somatostatin receptors in pituitary tumors.
Lania A; Mantovani G; Spada A
Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341
[TBL] [Abstract][Full Text] [Related]
7. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs.
Wildemberg LE; Neto LV; Costa DF; Nasciuti LE; Takiya CM; Alves LM; Rebora A; Minuto F; Ferone D; Gadelha MR
J Endocrinol Invest; 2013 Jan; 36(1):38-43. PubMed ID: 22472799
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Sánchez-Sánchez R; Chimelli L; Kasuki L; Luque RM; Gadelha MR
Sci Rep; 2019 Feb; 9(1):1122. PubMed ID: 30718563
[TBL] [Abstract][Full Text] [Related]
9. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.
Luque RM; Ibáñez-Costa A; Neto LV; Taboada GF; Hormaechea-Agulla D; Kasuki L; Venegas-Moreno E; Moreno-Carazo A; Gálvez MÁ; Soto-Moreno A; Kineman RD; Culler MD; Gahete MD; Gadelha MR; Castaño JP
Cancer Lett; 2015 Apr; 359(2):299-306. PubMed ID: 25637790
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
Taboada GF; Luque RM; Neto LV; Machado Ede O; Sbaffi BC; Domingues RC; Marcondes JB; Chimelli LM; Fontes R; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2008 Mar; 158(3):295-303. PubMed ID: 18299461
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and gsp status as predictors of octreotide LAR responsiveness in acromegaly.
Vieira Neto L; Taboada GF; Gadelha MR
Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1288-95. PubMed ID: 19169483
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
Park C; Yang I; Woo J; Kim S; Kim J; Kim Y; Sohn S; Kim E; Lee M; Park H; Jung J; Park S
Endocr J; 2004 Apr; 51(2):227-36. PubMed ID: 15118275
[TBL] [Abstract][Full Text] [Related]
14. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U
Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991
[TBL] [Abstract][Full Text] [Related]
15. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
16. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression.
Kasuki L; Vieira Neto L; Wildemberg LE; Colli LM; de Castro M; Takiya CM; Gadelha MR
Endocr Relat Cancer; 2012 Jun; 19(3):L25-9. PubMed ID: 22420004
[No Abstract] [Full Text] [Related]
17. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly.
Venegas-Moreno E; Vazquez-Borrego MC; Dios E; Gros-Herguido N; Flores-Martinez A; Rivero-Cortés E; Madrazo-Atutxa A; Japón MA; Luque RM; Castaño JP; Cano DA; Soto-Moreno A
J Cell Mol Med; 2018 Mar; 22(3):1640-1649. PubMed ID: 29266696
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic expression of SSTR2 and 5 by immunohistochemistry and by RT/PCR is not associated with the pharmacological response to octreotide.
Gonzalez B; Vargas G; Ramirez C; Asa S; Cheng S; Sandoval C; Mercado M
Endocrinol Nutr; 2014 Dec; 61(10):523-30. PubMed ID: 25008035
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
Lima GA; Wu Z; Silva CM; Barbosa FR; Dias JS; Schrank Y; Strasburger CJ; Gadelha MR
Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
[TBL] [Abstract][Full Text] [Related]
20. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
